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Background: Shaoyao decoction (SYD) is a traditional Chinese medicine prescription formulated by Liu Wan-Su, a
master of traditional Chinese medicine in Jin-Yuan Dynasty. SYD is effective in treating ulcerative colitis. Paeonol, a
component of SYD, inhibits colorectal cancer (CRC) cell proliferation and induces CRC cell apoptosis. In this study,
azoxymethane (AOM)/dextran sodium sulfate (DSS)–induced colitis-associated CRC (caCRC) model and CRC cell lines
were used to examine the effects of SYD on CRC in vivo and in vitro.
Methods: A translational medicine strategy based on phytomics quality control was adopted. Liquid chromatography
was employed for the chemical characterization and chemical fingerprinting of SYD. Protein expression and
macrophage existence were determined by immunohistochemistry and western blot. Serum cytokines were
quantified by Luminex assay.
Results: AOM/DSS-induced caCRC phenotypically resembled human caCRC. SYD significantly increased the survival
rate of the mice, ameliorated the general well-being of the mice, and reduced the incidence and multiplicity of colonic
neoplasms. SYD inhibited epithelial–mesenchymal transition (EMT), as indicated by upregulated epithelia cadherin and
downregulated neuronal cadherin, fibronectin, vimentin, and transcription factor Snail. SYD reduced the expression
levels of serum interleukin 1β, interleukin-6, tumor necrosis factor α, tumor-associated macrophages, and p65. These
results showed that SYD can attenuate proinflammatory cytokines and inhibit EMT.
Conclusions: SYD ameliorates caCRC by suppressing inflammation and inhibiting EMT. SYD might be an
alternative therapy for caCRC.
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Approximately 142,820 (9%) and 50,830 (9%) new cancer
cases and deaths of colorectal cancer (CRC) were reported
in the US in 2013, respectively [1]. CRC is the third most
common cancer in men and the second in women world-
wide [2]. Ulcerative colitis, familial adenomatous polyp-
osis, and hereditary nonpolyposis colon cancer syndrome
are the three highest risk groups for developing CRC. In a
metaanalysis based on 116 studies, the overall prevalence
of colorectal cancer in patients with ulcerative colitis was
3.7%. The risk of colorectal cancer increases by 8% in
20 years and by 18% in 30 years [3]. The pathogenesis
of colorectal cancer in patients with ulcerative colitis is
triggered by inflammation-dependent mechanisms [4].
Furthermore, ameliorating inflammation can control
inflammation-mediated reactive oxygen species, microsat-
ellite instability, telomere shortening, and chromosomal
instability [4].
Shaoyao decoction (SYD) is a canonical Chinese medi-
cine prescription formulated by Liu Wan-Su in “Plain
Questions - anthology on proper therapy for Qi disorder
and pathogenesis to save life” in Jin-Yuan dynasty (AD
1186). SYD is commonly used to treat various inflamma-
tory bowel diseases by clearing heat and damp, removing
stasis and toxin in the intestine [5]. SYD is effective in
ameliorating the major manifestations of ulcerative colitis,
such as hematochezia, abdominal pain, diarrhea, and
mucosal defense impairment [6,7]. SYD enhances mucous
cell proliferation, decreases exfoliated mucosal cell prolifer-
ation, and prevents lamina propria edema and neutrophil
infiltration [8]. SYD also exerts anti-inflammatory effects
that can decrease the expression of intercellular adhesion
molecule 1 (ICAM-1) and tumor necrosis factor α (TNF-α)
and increase the expression of interleukin (IL)-10 in colon
tissues [9]. Paeonol, the primary phenolic component in
Radix Paeoniae Alba (Shaoyao), reduces HT29 cell pro-
liferation by downregulating cyclooxygenase-2 and
upregulating p27 [10]. Paeonol induces LoVo cell apop-
tosis by increasing intracellular calcium concentration
[11]. However, whether or not SYD can prevent colitis-
associated CRC (caCRC) remains elusive.
The epithelial–mesenchymal transition (EMT) serves
important functions in the formation of body plan and
the differentiation of multiple tissues [12]. EMT is a
process in which epithelial cells trans-differentiate and
acquire invasive mesenchymal phenotype. Clinical analysis
[13] and animal experiments [14] demonstrated that EMT
contributes to the loss of intestinal epithelial cells; thus,
EMT is recognized as a major contributor to the patho-
genesis of inflammatory bowel diseases. Transforming
growth factor β (TGF-β), TNF-α, and nuclear factor κB
(NF-κB) participate in inflammation development; these
factors are also crucial for the initiation of EMT [15]. In
the present study, the functions of EMT in azoxymethane(AOM)/dextran sodium sulfate (DSS)–induced caCRC
[16] were evaluated to confirm whether or not SYD can
inhibit caCRC through EMT regulation.
Materials and methods
SYD preparation
SYD was composed of nine commonly used herbs: Radix
Paeoniae Alba, Radix Angelicae Sinensis, Rhizoma Coptidis,
Semen Arecae, Radix Aucklandiae, Radix Et Rhizoma
Glycyrrhizae, Radix Et Rhizoma Rhei, Radix Scutellariae,
Cortex Cinnamomi. The raw herbs for SYD were pur-
chased from the affiliated Nan Fang Hospital of Southern
Medical University. These were mixed in the ratio of
30:15:15:6:6:6:9:15:7.5 (dry weight). Aqueous extracts of
SYD were extracted at 80°C by stirring for 1 h using 10
volumes of distilled water (v/m). The extracts were cen-
trifuged at 1,500 g at room temperature. To obtain the
semisolid SYD solution, the supernatant was collected
and subjected to condensation under reduced pressure
at 70°C [17]. The quality of SYD was confirmed by
HPLC analysis (Additional file 1: Figures S1 and S2,
Table S1). SYD was suspended again in 0.9% saline at a
final concentration of 2 g/mL. The solution was stored
in aliquots at −20°C.
Animals and experimental procedure
All procedures involving laboratory animal use were in
accordance with the guidelines of the Instituted Animal
Care and Use Committee of Southern Medical University.
All protocols were submitted and validated by Animal
Care Ethics Committee of Southern Medical University
(No. 2012–055). 6 and 8 weeks male C57BL/6 J mice
weighting 15–20 g (specific pathogen-free) were obtained
from the Laboratory Animal Center of Southern Medical
University. The animals were maintained under controlled
conditions (22°C, 12-h/12-h dark/light cycle) in a conven-
tional animal colony. There were 65 mice used in the
study, 15 mice in control group, 30 in model group and
20 in SYD group. At the end of the study, there were 15
surviving mice in control group, 7 in model group and 12
in SYD group, respectively.
Procedures of induction of caCRC model by AOM
and DSS was shown in Figure 1A [16]. At week 2, mice
were injected with AOM (10 mg/kg, i.p.). After 1 week,
3% DSS (International Lab, Chicago, IL, USA) was added
to the drinking water for 7 days followed by 14 days of
tap water for recovery. This cycle was repeated twice.
SYD (7.12 g/kg) or equivalent normal saline was ad-
ministered by gavage using a tube twice a day. The mice
were killed by cervical dislocation at week 16 and the
colons (from the ileocecal junction to the anal verge)
were removed. After measuring the length and weight,
the colons were cut longitudinally along the main axis,
washed with phosphate-buffered saline (pH 7.4, 4°C) and
Figure 1 Effects of SYD on colitis-associated colon carcinogenesis was evaluated in C57BL/6 J mice. (A) Experimental protocol for
colitis-associated colon carcinogenesis model. (B) Effect of SYD on the body weight of mice. (C) Effect of SYD on the survival ratio of mice. SYD
prolonged animal survival (P = 0.032, vs. Model). Data are presented as mean ± SD vs. control and model.
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of pre-neoplastic and neoplastic lesions (dysplasia and
carcinoma) in the colons were recorded based on gross
examination. The size of dysplasia was measured by an
ocular micrometer. After gross examination, the colons
were cut into pieces at about 1 cm intervals. Samples
were then fixed in 10% buffered formalin (pH 7.4) or
kept in 10 volumes of RNAlater Solution (Ambion, Life
technologies, Carlsbad, CA, USA). Remaining samples
were flash-frozen in liquid nitrogen and stored at −80°C
for further immunohistochemistry, PCR and protein
analysis.Reagents
Paeonolsilatie sodium was purchased from Jinling Pharma-
ceutical Co., Ltd. Dimethyl sulfoxide (DMSO) and thiazolyl
blue tetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). RPMI 1640, FBS
and antibiotics were purchased from Invitrogen (Gibco,
Grand Island,NY, USA). Snail homolog 1 (Drosophila) was
purchased from FulenGen (Genecopoeia,USA).
Cell viability assays
MTT assay was used to analyze the effects of paeonol
and SYD on cell viability in two kinds of colorectal
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routinely maintained in RPMI 1640, supplemented
with 10% FBS and antibiotics (50 U/ml of penicillin
and 50 μg/ml streptomycin) at 37°C in a humidified
atmosphere containing 5% CO2. Cell number was mea-
sured on a standard microscope by manual counting of
cells using a grid with an area of 0.25 mm2. 1 × 104 Cells
were seeded on 96-well plates in a 100 μl volume. The
MTT assay was performed by addition of MTT to a final
concentration of 0.5 mg/ml of medium. After 4 h, the
medium was removed, and 150 μl of DMSO was added to
each well. After 10 min of shaking at room temperature,
150 μl of soluble material was placed into a new 96-well
plate, and absorbance at 562 nm was read with a back-
ground subtraction at 660 nm.
Cell culture and transfection
HCT116 cell line was cultured in RPMI 1640, supple-
mented with 10% FBS and antibiotics (50 U/ml of penicil-
lin and 50 μg/ml streptomycin) at 37°C in a humidified
atmosphere containing 5% CO2. For transfection,cells
were seeded in a 6-well plate 24 h before the experiment.
The cells were transfected with Snail 1 plasmid using the
Attractene reagent (Qiagen, Germany) according to the
manufacture’s protocol.
Histopathological assessment
For histopathological examination, formalin fixed, paraffin-
embedded colon tissues were cut into serial sections (5 μm)
and stained with haematoxylin and eosin (H&E). Histo-
logical alternations such as dysplasia and carcinoma were
verified. Assessment of dysplasia and cancer was based on
the criteria set forth in the Mouse Models of Intestinal
Cancers consensus report: location, presence/absence of
prolapse/herniation, size, dysplasia grade, invasion level,
presence of desmoplasia and presence of irregular architec-
ture [18]. Carcinoma was defined as high-grade dysplasia of
colonic mucosa which invaded beyond the muscularis
mucosa and into the submucosa [16].
Immunohistochemistry
Paraffin-embedded colon sections were deparaffinized,
rehydrated, and pre-treated with hydrogen peroxidase in
PBS buffer. Heat-induced antigen retrieval was performed.
After blocking with the appropriate antisera sections were
incubated with anti-Proliferating cell nuclear antigen
(PCNA) (Thermo scientific, clone PC10, 1:300), anti-β-
catenin (Cell Signaling Technology, CST, clone 6B3; 1:100
dilution), anti-p53 (Leica-microsystems, clone CM5, 1:100
dilution), anti-COX-2 (Thermo scientific, 1:100 dilution),
anti-E-cadherin ( CST, clone24E10, 1:200 dilution), anti-
N-cadherin (Millipore, clone EPR1792Y, 1:50 dilution),
anti-fibronectin (Epitomics, clone F14, 1:200 dilution),
anti-vimentin (CST, clone D21H3, 1:50 dilution), NF-κB(Abcom, clone E379, 1:100 dilution), F4/80 (Santa Cruz
Biotechnology, clone BM8, 1:50 dilution). After incubation
with HRP-conjugated secondary antibody and tyramide
amplification followed by streptavidin-HRP, positive sig-
nals were visualized by DAB kit and counter-stained with
hematoxylin. Five randomly selected fields from each
section were examined at a magnification of 400× and
analyzed using NIS-Elements. The positive content was
calculated using the following formula: positive content
(PC) =mean optical density × positive area.
Western blot analysis
Colonic tissues were homogenized in liquid nitrogen,
dissolved in lysis buffer [7 mol/L urea, 2 mol/L thiourea,
4% (w/v) CHAPS, 20 mmol/L Tris, 65 mmol/L DTT, 0.2%
pharmalyte 3/10 ampholyte] supplemented with 8 μl of
protease inhibitor cocktail (The protease inhibitor cocktail
include AEBSF hydrochloride 500 μM, Aprotinin 150 nM,
E-64 protease inhibitor 1 μM, EDTA disodium 0.5 mM and
Leupetin hemisulfate 1 μM. Calbiochem, San Diego, CA,
USA). Samples were then centrifuged at 15,000 g for
30 min at 4°C. Protein concentrations were determined by
modified Bradford assay and resolved by SDS-PAGE, trans-
ferred to PVDF membranes and blocked in 5% non-fat milk
in Tris-buffered saline (TBST, 100 mM NaCl, 50 mM Tris,
0.1% Tween-20, pH 7.5). Membranes were incubated over-
night with primary antibodies [anti-PCNA (CST, clone
PC10, 1:1000 dilution), anti-β-catenin (CST, clone 6B3,
1:1000 dilution), anti-p53 (CST, clone 1C12, 1:1000 dilu-
tion), or anti-COX-2 (CST, clone D5H5, 1:1000 dilution),
anti-E-cadherin (CST, clone 24E10, 1:1000 dilution), anti-
N-cadherin (Millipore, clone EPR1792Y, 1:50000 dilution),
anti-Vimentin (CST, clone D21H3, 1:1000 dilution), anti-
Snail (CST, clone C15D3, 1:1000 dilution)] at 4°C. This was
followed by incubation with horseradish peroxidase (HRP)
conjugated secondary antibodies. Protein bandings were vi-
sualized with enhanced chemiluminescence reagents (ECL,
GE Healthcare Bio-science, Uppsata, Sweden). The images
were captured with a CCD system (imagestation 2000 MM,
Kodak, Rochester, NY, USA). Quantitative analysis of sig-
nals was performed using Molecular Imaging Software
Version 4.0, provided by Kodak 2000 MM System. The
optical density was normalized by β-actin.
Cytokine measurement by multiplex immunoassay
The levels of interleukin-1β (IL-1β), IL-6 and TNF-α in
the serum were measured using mice cytokine multiplex
kit (Millipore, Billerica, MA, USA). Quantification of cyto-
kines was performed using the Luminex system (Austin,
TX, USA) [19].
Statistical analysis
Each experiment was repeated at least three times. Data
were presented as mean ± SD. All data were analyzed using
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IL, USA). Survival rate was analyzed with Kaplan-Meier
survival analysis. Data between two groups were compared
with 2-independent samples tests. Ranked data were ana-
lyzed by nonparametric test (K Independent Samples
Test). Mean values of data from more than 3 groups were
analyzed by one-way analysis of variance (ANOVA). A
value of P < 0.05 was considered as statistically significant.
Result
SYD increased the survival rate of mice treated with
AOM/DSS
Body weight loss and bloody stools were observed in
mice acutely exposed to DSS. These symptoms were
relieved during the recovery period (Figure 1B). The colon
weight was increased and the length was shortened signifi-
cantly in the mice that received both AOM and DSS com-
pared with the control mice (Table 1). The significant
increases in colon weight and colon length ratio were
caused by apparent mucosal thickening. SYD substantially
ameliorated the body weight fluctuation and mucosal
thickening. The Kaplan–Meier survival curves showed
that SYD significantly increased the survival rate of the
mice (Figure 1C).
SYD reduced the incidence and multiplicity of colonic
neoplasms and oncogenic protein expression
The colonic neoplasm formation rate was 100% in the
mice treated with AOM/DSS. Neoplasms were principally
distributed in the middle and distal colon (Figure 2A).
The total multiplicity of colorectal neoplasms decreased
by 42.8% after SYD treatment (P < 0.01, Table 2). More-
over, SYD significantly retarded the development of large
neoplasms (diameter > 3 mm) by 59.2% (Figure 2B, Table 2).
The tumour weight and tumour volume were decreased by
SYD (Figure 2C). The neoplasms in the colon were mostly
tubular adenoma or adenocarcinoma according to the cri-
teria of Mouse Models of Intestinal Cancers (Figure 2D).
The neoplasms was mostly high-differentiation with inva-
sion in model group.SYD treatment could ameliorate level
of differentiation and invasion of neoplasms (P = 0.041,
Table 3).
The expression levels of proliferating cell nuclear anti-
gen (PCNA) and β-catenin increased in dysplastic andTable 1 Colon and spleen assessment in mice
Group Colon
Weight(g) Length(cm)
Control (n = 15) 0.23 ± 0.022 9.14 ± 0.628
Model (n = 7) 0.54 ± 0.059△ 5.75 ± 0.477△
SYD (n = 12) 0.37 ± 0.049* 7.56 ± 1.133#
*: P < 0.01 VS Model; #: P < 0.05 VS Model.
△: P < 0.01 VS Control.neoplastic lesions (Figure 3A and Figure 3B). Intense nu-
clear staining for p53 (CM5 clone: detects both mutant
and wild-type forms) was detected in the neoplastic
epithelium and in nondysplastic crypts, implicating the
involvement of p53 mutation in our AOM/DSS-induced
caCRC model [18]. The expression levels of these neoplas-
tic markers suggested that AOM/DSS-induced caCRC
phenotypically resembled human caCRC even though the
expression of COX-2 was not high in adenocarcinoma
(Figures 3A and 3B, Table 4).
SYD and Paeonol inhibited CRC cell proliferation
SYD significantly decreased cell viability in a time- and
dose-dependent manner; the dose ranged from 0 mg/mL
to 8 mg/mL. The viabilities of SW480 and HCT116 cells
decreased to 50.2266% and 53.6704% after 24 h of treat-
ment with 2 mg/mL SYD (Figure 4A). Paeonol, an ingre-
dient of Radix Paeoniae Alba, significantly decreased cell
viability in a time-and dose-dependent manner; the dose
ranged from 0 mM/L to 0.8 mM/L. The viabilities of
SW480 and HCT116 cells decreased to 48.0659% and
51.3992% after 48 h of treatment with 0.4 mM /L Paeonol
(Figure 4B).
SYD and Paeonol decreased oncogenic proteins in CRC cells
SYD and Paeonol decreased the expression levels of
PCNA, β-catenin, p53, and COX-2 in CRC cells in a
dose-dependent manner. (Figure 5A and Figure 5B,
Table 5 and Table 6).
SYD inhibited Snail-induced EMT
E-cad was moderately expressed in the epithelial cells of
the control group but was downregulated in the epithelial
cells of the model group. N-cadherin (N-cad) and fi-
bronectin were strongly expressed and vimentin was
moderately expressed in the model group, suggesting
the occurrence of EMT (Figures 6A). SYD significantly
increased the expression of E-cad and decreased the
expression of N-cad, fibronectin, and vimentin (Figures 6A,
Table 4). Western blot analysis further confirmed the
effects of SYD on the expression of E-cad, N-cad, and
vimentin. Snail was upregulated in the model group,
and it was downregulated by SYD (Figure 6B, Table 4).Spleen
W/L ratio Weight(g) SW/BW ratio
0.02 ± 0.003 0.07 ± 0.005 0.003 ± 0.0002
0.09 ± 0.008△ 0.35 ± 0.036△ 0.018 ± 0.0019△
0.05 ± 0.003* 0.18 ± 0.061* 0.007 ± 0.0025*
Figure 2 Effects of SYD on the burden of colonic neoplasms. (A) Microscopic view of colon in mice. (B) Effect of SYD on colonic neoplasm
size. SYD significantly suppressed tumor growth and reduced neoplasm size. Data are presented as mean ± SD. *P < 0.01 vs. model, # P < 0.05 vs.
model. (C) Effects of SYD on tumour weight and tumour volume in each mice. SYD significantly decreased tumour weight and tumour volume.
(D) Most colorectal neoplasms were histologically consistent with tubular adenoma or adenocarcinoma. Histological studies were carried out
through hematoxylin and eosin staining as previously described. (Da) Normal colon; (Db) tubular adenoma; (Dc) adenocarcinoma. 40 × for all,
scale bar = 100 μm. The analysis of differentiation and invasion is shown in Table 3 (P = 0.041).
Table 2 Number and size of neoplasms in colon in mice
Group Number of neoplasms
Total number >3 mm 1-3 mm <1 mm
Control (n = 15) 0.00 ± 0.000 0.00 ± 0.000 0.00 ± 0.000 0.00 ± 0.000
Model (n = 7) 10.25 ± 1.669△ 5.25 ± 1.488△ 4.13 ± 0.835△ 1.13 ± 0.354△
SYD (n = 12) 5.86 ± 1.574* 2.14 ± 1.069* 1.14 ± 0.378* 2.57 ± 0.976#
*: P < 0.01 VS Model; #: P < 0.05 VS Model.
△: P < 0.01 VS Control.
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Table 3 Analysis of differentiation and invasion
Group Differentiation and invasion (number)
PD MD HD-I HD-NI
Model (n = 7) 0 0 7 0
SYD (n = 12) 0 1 4 7
PD: poor differentiation; MD: middle differentiation.
HD-I: high differentiation and invasion.
HD-NI: high differentiation and noninvasion.
Figure 3 Effects of SYD on oncogenic protein expression. (A) Immuno
tissues or normal colonic tissues. β-catenin, p53, and PCNA were localized
β-catenin, Cox2, p53, and PCNA expression in colonic tissues. The expressio
with the model group. Semiquantitive analysis of these proteins is showed
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EMT, induced the upregulation of N-cad and vimentin.
SYD and Paeonol decreased the expression of N-cad
induced by Snail overexpression. (Figure 5C, Table 5
and Table 6)
SYD decreased serum cytokines, macrophage proliferation,
and NF-κB expression
The number of macrophages and the expression of NF-κB
were increased significantly in the model group compared
with those in the control group; SYD counteracted thesehistochemical staining of β-catenin, Cox2, p53, and PCNA in tumor
within the nuclei. 200× for all, scale bar = 100 μm. (B) Western blot of
n levels of these proteins were reduced in the SYD group compared
in Table 4.
Table 4 Semiquantitive analysis of IHC and WB
Control Model SYD
β-catenin-IHC 0.52 ± 0.39 4.12 ± 1.83△ 2.23 ± 1.92#
Cox2-IHC 0.97 ± 0.30 6.18 ± 2.02△ 3.06 ± 1.53*
p53-IHC 0.66 ± 0.45 6.03 ± 2.17△ 3.33 ± 2.07#
PCNA-IHC 1.26 ± 0.60 5.63 ± 2.21△ 3.06 ± 1.95#
E-cadherin-IHC 0.50 ± 0.39 0.09 ± 0.07 3.44 ± 1.69#
N-cadherin-IHC 0.51 ± 0.38 8.10 ± 1.52△ 4.22 ± 1.19#
Fibronectin-IHC 0.80 ± 0.81 7.48 ± 2.08△ 4.14 ± 1.59#
Vimentin-IHC 0.24 ± 0.28 4.92 ± 1.73△ 2.84 ± 1.46#
NF-κB-IHC 0.89 ± 0.48 8.29 ± 1.53△ 4.69 ± 1.83#
F4/80-IHC 0.03 ± 0.04 6.05 ± 1.61△ 3.89 ± 1.54#
β-catenin-WB 0.008 ± 0.006 0.750 ± 0.292△ 0.250 ± 0.270#
Cox2-WB 0.277 ± 0.070 0.677 ± 0.239▲ 0.307 ± 0.074#
p53-WB 0.064 ± 0.040 0.370 ± 0.105△ 0.165 ± 0.073#
PCNA-WB 0.089 ± 0.0226 0.282 ± 0.091△ 0.158 ± 0.039#
E-cadherin-WB 0.723 ± 0.229 0.194 ± 0.099▲ 0.560 ± 0.185#
N-cadherin-WB 0.096 ± 0.055 0.620 ± 0.271▲ 0.262 ± 0.131#
Vimentin-WB 0.217 ± 0.038 0.583 ± 0.200▲ 0.290 ± 0.110#
Snail-WB 0.085 ± 0.037 0.423 ± 0.146△ 0.187 ± 0.096#
Claudin-1-WB 0.018 ± 0.017 0.280 ± 0.141△ 0.109 ± 0.027#
*: P < 0.01 VS Model; #: P < 0.05 VS Model.
△: P < 0.01 VS Control; ▲: P < 0.05 VS Control.
IHC: Immunohistochemistry; WB: Western blot.
Figure 4 Effects of SYD and Paeonol on colorectal cancer cells in vitro
exposed to 0–8 mg/mL SYD and incubated for 12 and 24 h. Cell viability was
the cell viability compared to 0-only. *P < 0.01 vs. 0 mg/mL; #P < 0.05 vs. 0 mg
were exposed to 0–0.8 mM/L Paeonol and incubated for 24 and 48 h. Cell via
percentage of the cell viability compared to 0-only. *P < 0.01 vs. 0 mM/L; #P <
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upregulated in the model group and were significantly
inhibited by SYD (Figure 7B).
Discussion
Variations in climatic conditions, geographic locations,
and harvesting, processing, and extraction methods could
challenge the quality control of herbal extracts from
Chinese compound prescriptions [20]. In the present
study, several specific chemical markers and batch-to-
batch comparison for quality controls were utilized. This
strategy (i.e., formulomics) was based on liquid chroma-
tography for chemical characterization and chemical
fingerprinting of SYD [21,22]. The strict extract quality
control of SYD is important to translate the TCM formula
to clinical drugs [21].
Basing on the capacity of SYD to downregulate the ex-
pression of proinflammatory cytokines, such as ICAM-1
and TNF-α, we hypothesized that SYD ameliorates caCRC
by suppressing inflammation [23,24]. Repeated DSS
administration causes chronic inflammation, and AOM
induces the formation of O6-methylguanine upon metallic
activation [25]. Therefore, DSS in combination with AOM
resulted in 100% incidence of colonic neoplasms in mice
in the present experiment. DSS administration caused
mass death in the model group; the effect of this drug was
alleviated by SYD treatment. Tumor numbers were re-
duced and CRC cell proliferation was inhibited by SYD.. (A) Effects of SYD on proliferation of SW480 and HCT116. Cells were
measured by MTT methods and values were expressed as percentage of
/mL. (B) Effects of Paeonol on proliferation of SW480 and HCT116. Cells
bility was measured by MTT methods and values were expressed as
0.05 vs. 0 mM/L.
Figure 5 Effects of SYD and Paeonol of oncogenic protein
expression on colorectal cancer cells, HCT116, SW480. (A)
Western blot of β-catenin, Cox2, p53 and PCNA expression in SW480
and HCT116 exposed to 0–4 mg/mL SYD. The expression levels of these
proteins were reduced in a dose-dependent manner. Semiquantitive
analysis of these proteins is showed in Table 5. (B) Western blot of
β-catenin, Cox2, p53 and PCNA expression in SW480 and HCT116
exposed to 0–0.4 mM/L Paeonol. The expression levels of these
proteins were reduced in a dose-dependent manner. Semiquantitive
analysis of these proteins is showed in Table 6. (C) Western blot
of E-cad, N-cad and vimentin expression in SW480 with Snail
overexpression exposed to 0–4 mg/mL SYD and 0–0.4 mM/L Paeonol.
The expression levels of N-cad and vimentin were reduced in a
dose-dependent manner, while E-cad was increased in a
dose-dependent manner. Semiquantitive analysis of these
proteins is showed in Tables 5 and 6.
Table 5 Semiquantitive analysis of WB of SYD on HCT116
and SW480
0 mg/mL 2 mg/mL 4 mg/mL
β-catenin-H 0.61 ± 0.03 0.33 ± 0.06* 0.193 ± 0.07*
Cox2-H 0.24 ± 0.03 0.13 ± 0.03* 0.09 ± 0.03*
p53-H 0.52 ± 0.06 0.35 ± 0.06# 0.19 ± 0.06*
PCNA-H 0.32 ± 0.06 0.17 ± 0.08# 0.11 ± 0.04*
β-catenin-S 0.68 ± 0.009 0.34 ± 0.06* 0.28 ± 0.02*
Cox2-S 0.08 ± 0.01 0.02 ± 0.01* 0.008 ± 0.001*
p53-S 0.55 ± 0.10 0.34 ± 0.08# 0.25 ± 0.09*
PCNA-S 0.32 ± 0.12 0.09 ± 0.06# 0.06 ± 0.03*
E-cadherin-SS 0.09 ± 0.03 0.30 ± 0.08# 0.51 ± 0.12*
N-cadherin-SS 0.22 ± 0.05 0.09 ± 0.02* 0.06 ± 0.02*
Vimentin-SS 0.53 ± 0.06 0.35 ± 0.07# 0.15 ±0.07*
*: P < 0.01 VS 0; #: P < 0.05 VS 0; H: HCT116; S: SW480; SS: SW480 with
Snail overexpression.
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fects by inhibiting CRC cell proliferation.
Increased PCNA and β-catenin expression suggested
that DSS/AOM-induced neoplasm resembled human
caCRC. The increase in β-catenin due to the constitutive
Wnt activation for AOM induces mutations in the exon
3 of Ctnnb [25]. Wild-type p53 is a rapidly degraded
protein with a low cellular level [26]; thus, the accumu-
lation of p53 in the model group also characterizes
caCRC for the early loss of p53 function [18]. Downreg-
ulation of PCNA, β-catenin, and p53 by SYD further
confirmed the efficacy of SYD in DSS/AOM-induced
caCRC.
EMT disrupts cell–cell adherence, causes apico-basal
polarity loss, and triggers matrix remodeling to promote
CRC pathogenesis and metastasis [27]. EMT endows cellsTable 6 Semiquantitive analysis of WB of Paeonol on
HCT116 and SW480
0 mM/L 0.2 mM/L 0.4 mM/L
β-catenin-H 0.38 ± 0.04 0.22 ± 0.03* 0.13 ± 0.04*
Cox2-H 0.17 ± 0.07 0.04 ± 0.008# 0.01 ± 0.002*
p53-H 0.35 ± 0.14 0.17 ± 0.07# 0.08 ± 0.04*
PCNA-H 0.37 ± 0.09 0.19 ± 0.08# 0.09 ± 0.04*
β-catenin-S 0.21 ± 0.03 0.13 ± 0.04# 0.05 ± 0.03*
Cox2-S 0.14 ± 0.04 0.05 ± 0.01* 0.008 ± 0.002*
p53-S 0.48 ± 0.18 0.20 ± 0.08# 0.10 ± 0.05*
PCNA-S 0.22 ± 0.04 0.12 ± 0.04# 0.08 ± 0.06#
E-cadherin-SS 0.04 ± 0.03 0.23 ± 0.06* 0.35 ± 0.08*
N-cadherin-SS 0.42 ± 0.06 0.30 ± 0.08# 0.15 ± 0.03*
Vimentin-SS 0.37 ± 0.05 0.18 ± 0.05* 0.07 ± 0.04*
*: P < 0.01 VS 0; #: P < 0.05 VS 0; H: HCT116; S: SW480; SS: SW480 with
Snail overexpression.
Figure 6 Effects of SYD on EMT-related protein expression. (A) Immunohistochemical staining of E-cadherin, N-cadherin, fibronectin,
vimentin in tumor tissues or normal colonic tissues. 200 × for all, scale bar = 100 μm. (B) Western blot of E-cadherin, N-cadherin, vimentin, Snail,
and claudin-1 in colonic tissues. E-cadherin was significantly deficient in the model group. E-cadherin was upregulated while N-cadherin, fibronectin,
and vimentin were downregulated by SYD treatment. These effects were confirmed by Western blot. Semiquantitive analysis of these proteins is
showed in Table 4.
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http://www.translational-medicine.com/content/12/1/105with migratory and invasive capacity, induces stem cell
properties, prevents apoptosis and senescence, and con-
tributes to immunosuppression [12]. In the present study,
SYD ameliorated DSS/AOM-induced EMT, as indicated
by upregulated E-cad and downregulated N-cad, fibronec-
tin, and vimentin. In a previous report, Snail overexpression
results in dramatic changes in signaling pathways that
are involved in EMT and contributes to the acquisition of
stem/progenitor-like character [28]. Snail also repressesepithelial gene expression and thereby promotes EMT and
tumor invasion by activating the beta-catenin pathway
[29]. SYD and paeonol significantly decreased Snail-
induced expression of N-Cad and vimentin. This result
suggested that SYD executed its protective activity by
downregulating Snail-induced EMT [28,29].
The major function of SYD was to resolve colorectal
inflammation through heat clearing and detoxification.
Paeonol decreases lipopolysaccharide-induced TNF-α,
Figure 7 Effects of SYD on TAM and cytokine profile. (A) Immunohistochemical staining of NF-κB and F4/80 in tumor tissues or normal
colonic tissues .200 × for all, scale bar = 100 μm. High expression levels of NF-κB and F4/80 were detected in the model group. SYD decreased
NF-κB expression and F4/80-positive cells. Semiquantitative analysis of these proteins is shown in Table 4. (B) Luminex assay of IL-1β, IL-6, and
TNF-α levels in serum. Serum contents of IL-1β, IL-6, and TNF-α were reduced by SYD. Data are presented as mean ± SD. *P < 0.01 vs. model,
#P < 0.05 vs. model; △P < 0.01 vs. control,▲P < 0.0 5 vs. control. (C) A model of SYD function in caCRC.
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http://www.translational-medicine.com/content/12/1/105IL-1β, and IL-6 in RAW 264.7 cells by deactivating
IκBα [30]. In addition, the levels of TNF-α, IL-1β, and
IL-6 are significantly higher in CRC patients than in
controls [31]. In the present study, SYD decreased the
serum levels of IL-1β, IL-6, and TNF-α. Reduced IL-1βfrom macrophages may attenuate the stabilization of
β-catenin and deactivate Wnt target genes in CRC cells
[32]. Repressed TNF-α and IL-6 inhibit tumor growth
in experimental models of colitis-associated cancer
[33]. In the present study, macrophage infiltration and
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http://www.translational-medicine.com/content/12/1/105NF-κB expression were decreased. IL-1β, IL-6, and
TNF-α are multifunctional NF-κB-regulated cytokines
that feature κB or κB-like binding motifs in their 5′
regulatory region [34,35]. Thus, we supposed that SYD
can attenuate caCRC by suppressing NF-κB activation
and related inflammatory responses [36].
Mutant p53 accumulated in inflamed colon and in
cancerous glands concomitantly with NF-κB activation
and sustained DNA damage. Mice were susceptible to
chronic inflammation. However, it also greatly accelerated
the inflammation-associated colon cancer under this situ-
ation [37]. TNF-α is a critical factor produced by macro-
phages to accelerate EMT [38]. This factor increases Snail
protein expression and Snail nuclear translocation to
initiate cancer invasion and metastasis through EMT
activation [27]. EMT can be induced by activating the
NF-κB pathway and enhancing Snail [39]. AOM exacer-
bated DSS-induced colitis to caCRC by triggering p53
mutation, β-catenin accumulation, and EMT induction
upon tumor-associated macrophage (TAM) infiltration,
and NF-κB promoted IL-1β, IL-6, and TNF-α release.
Therefore, SYD might ameliorate caCRC by suppressing
NF-κB activation and cytokine-induced EMT.
Conclusions
SYD repressed IL-1β, IL-6, and TNF-α, thereby inhibiting
Snail-induced EMT by attenuating TAM infiltration and
NF-κB activation [40-42] (Figure 7C).
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